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Ethnopharmacology relevance: A previous study indicated non-inferiority of GCSB-5 to celecoxib re-
garding efﬁcacy and safety in treating OA; however, the gastrointestinal (GI) safety data was limited to 12
weeks. Accordingly, a longer term study with a larger number of patients was necessary to establish the
GI safety of GCSB-5.
Aim of study: The primary goal was to determine the safety and efﬁcacy of 24-week use of GCSB-5. The
secondary goal was to compare the GI safety data of GCSB-5 with that of the previously reported Cel-
ecoxib Long-term Arthritis Safety Study (CLASS).
Method: This was a 24-week, multicenter, single-arm phase IV Study for the safety and efﬁcacy of GCSB-
5. A total of 761 patients were enrolled and 756 patients received at least one dose of GCSB-5. Among
them, 629 patients (82.7%) completed the 24 week follow up. The primary goal was to determine the
safety and efﬁcacy of GCSB-5 for 24 weeks. The secondary goal was to compare the GI safety data of
GCSB-5 with that of the previously reported Celecoxib Long-term Arthritis Safety Study (CLASS).
Results: The incidence of GI disorders of GCSB-5 was 23.7%. The annual rate of perforation, ulcer ob-
struction, or bleeding (PUB) incidence was 0.0%. The drop-out rate due to GI disorders following GCSB-5
use was 4.8%. Compared to celecoxib data from CLASS, the incidence of GI disorders (23.7% vs. 31.4%,r Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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C.-W. Ha et al. / Journal of Ethnopharmacology 189 (2016) 310–318 311po0.001), annual rate of PUB and gastroduodenal ulcers (0.0% vs 2.2%, p¼0.004), and drop-out rate due
to GI disorders following GCSB-5 use were signiﬁcantly low (4.8% vs 8.7%, po0.001). Efﬁcacy was proven
by signiﬁcant improvements in Western Ontario McMaster Questionnaire (WOMAC) scale, Korean Knee
Score (KKS), 100-mm pain visual analogue scale (VAS), and physician's global assessments of patient's
response to therapy (PGART).
Conclusions: The safety and efﬁcacy proﬁle of GCSB-5 are comparable to celecoxib. These results indicate
GCSB-5 is safe for a long-term treatment of knee OA patients.
Trial registration: ClinicalTrials.gov (NCT01604239).
& 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Osteoarthritis (OA) is a common disease that causes functional
disability and considerable medical care expenses (Conaghan et al.,
2008). Common pharmacologic treatments for OA include an-
algesics, non-steroidal anti-inﬂammatory drugs (NSAIDs), and cy-
clooxygenase-2 (COX-2) inhibitors (Manek and Lane, 2000). De-
spite the widespread use of NSAIDs, however, various adverse
drug reactions (ADRs) have been reported, including gastro-
intestinal (GI) complications (American College of Rheumatology
Subcommittee on Rheumatoid Arthritis Guidelines, 2002; Bom-
bardier, 2002; Song et al., 2007). Further, OA requires long-term
treatment, and prolonged use of NSAIDs can cause GI bleeding,
gastric ulcers, and other serious GI complications (Gabriel et al.,
1991; García Rodríguez and Jick, 1994; Hawkey, 1990).
A number of herbal medicines have been developed to treat OA
(Angermann, 2005; Lung et al., 2004; Ownby et al., 2014; Park et al.,
2013; Song et al., 2007; Yoo et al., 2014). One of these is GCSB-5
(Shinbaro
s
, Green Cross Corporation, Yongin, Korea), medicine ap-
proved in Korea at 2011, prepared from six puriﬁed oriental herbal
extracts including Saposhnikovia divaricata Schischk, Glycine max
Merrill, Cibotium barometz J. Smith, Eucommiaulmoides Oliver,
Achyranthes japonica Nakai, and Acanthopanax sessiliﬂorus Seem (Lee
and Cha, 2008; Lee and Cha, 2009; Cha and Lee, 2009; Cha and Lee,
2010). These herbs have played an important role in the medical care
of for thousands of years in Korea (Heo, 1999; Lee, 1978). For ex-
ample, Acanthopanax sessiliﬂorus and Eucommiaulmoides have been
known for relieving oxidative stress. Eucommiaulmoides has been
known to decrease interleukin-1β and tissue necrotic factor α. Sa-
poshnikovia divaricata and Cibotium barometz also showed anti-in-
ﬂammatory effect. These 6 medicinal herbal extracts used in pro-
ducing GCSB-5 have demonstrated anti-inﬂammatory and analgesic
effects (Kim et al., 2002, 2012; Lee et al., 2005), These results in-
dicated that GCSB-5 could be promising for the treatment of OA. A
phase III randomized double blind multicenter study revealed that
GCSB-5 is comparable in safety and efﬁcacy to the COX-2 inhibitor
celecoxib (Celebrex
s
) (Park et al., 2013). The study, however, lasted
only for 12 weeks and included only 198 patients, which does not
seem to be adequate to determine the comparative safety of GCSB-5.
Consequently, a longer term safety study in a larger number of pa-
tients is needed to establish the safety of GCSB-5 more decisively.
Accordingly, a 24-week single-arm phase IV study involving patients
with knee OA was conducted to determine the GI safety and efﬁcacy
of GCSB-5. Additionally, the GI safety results of GCSB-5 were com-
pared with the data from the previously reported Celecoxib Long-
term Arthritis Safety Study (CLASS) (Silverstein et al., 2000).2. Methods
2.1. Study design
This study was a multicenter single-arm phase IV clinical trial.
After a 2-week washout period, eligible patients wereadministered with the study drug for 24 weeks. The participants
were monitored at weeks 4, 12, and 24 by out-patient visits, and
by telephone at weeks 8, 16, and 20. The study protocol was ap-
proved by the institutional review boards of the participating
hospitals (listed in eTable 1, Additional ﬁle 1) and a written in-
formed consent was obtained from every participant enrolled.
2.2. Participants
Adult patients diagnosed with Kellgren and Lawrence stage I–III
knee joint OA according to American College of Rheumatology
(ACR) criteria were eligible to participate if OA symptoms were
stable for three months. Patients were excluded from the study if
they had other orthopedic diseases which could interfere with the
efﬁcacy evaluation, had used corticosteroids within the previous
12 weeks, had used psychotropic drugs or narcotic analgesics
within the previous 4 weeks, had a hypersensitivity to any one of
the six herbal ingredients, GI, renal, liver, or coagulation disorders,
or if they participated in any other clinical trial within the previous
4 weeks (eTable 2, Additional ﬁle 1).
2.3. Treatment and concomitant medications
A capsule of GSCB-5 contains 300 mg of dried extracts of the
mixture of six herbs in a ﬁxed ratio; Saposhnikovia divaricate
Schischk: Glycine max Merrill: Cibotium barometz J. Smith: Eucommia
ulmoides Oliver: Achyranthes japonica Nakai: Acanthopanax sessili-
ﬂorus Seem¼4.444:2.778:2.778:1.389:4.444:4.444. GCSB-5 was
manufactured with the following method. The six herbs were pow-
dered and boiled for 3 h in distilled water. The resulting extract was
ultra ﬁltrated and the substances with molecular weight over 10,000
were excluded to obtain the ﬁnal GCSB-5 extract. The ﬁltrate was
lyophilized and used for the manufacturing of GCSB-5 capsules.
Each participant took two GCSB-5 capsules (lot # 1518011,
300 mg each) twice per day (in the morning and evening) for 24
weeks. Low dose aspirin use for prevention of vascular events was
allowed (r300 mg/day). Other concomitant medications that the
investigator deemed would not affect the study outcomes were
likewise allowed. Acetaminophen up to 2600 mg per day or
4550 mg per week was allowed as a rescue medication.
The following drugs and therapies were prohibited during the
study period including the screening phase: topical medicines,
analgesics, NSAIDs, and oral corticosteroids; intra-articular corti-
costeroid injection; anti-ulcer drugs (except transient antacid use);
antibiotics for the treatment of Helicobacter pylori infection; pro-
ton pump inhibitors; H2 receptor antagonists; antineoplastics (e.g.,
methotrexate, tamoxifen); antidepressants; muscle relaxants;
psychotropic drugs; narcotic analgesics; anticonvulsants; therapy
to control pain including physical therapy and prolotherapy; and
other over-the-counter drugs for the treatment of OA.
2.4. Outcome measures
The primary safety outcome measure was the incidence of
C.-W. Ha et al. / Journal of Ethnopharmacology 189 (2016) 310–318312adverse events (AEs) related to the GI system. All of the AEs that
occurred during the study period were collected at each visit by
asking about any symptoms other than that of arthritis since the
last visit. The AEs were collected regardless of the severity or re-
lationship to the study drug. The AEs were classiﬁed according to
the terminology of the Medical Dictionary for Regulatory Activities
version 14.0 (MedRA 14.0) (Brown et al., 1999) and the AEs of GI
disorders were classiﬁed according to the system organ class (SOC)
from the MedRA 14.0. The secondary safety outcomes were the
incidence of PUB (perforation, ulcer obstruction or bleeding, de-
scribed in eTable 3 of Additional ﬁle 1) and the drop-out rate due
to GI disorders. All participants with suspected PUB events were
referred to GI specialists for PUB diagnosis, treatment, and related
tests. For those participants, the investigator collected diagnostic
and treatment information and submitted the GI event report
form to the GI event committee (GEC) for adjudication. The GEC
was comprised of independent GI specialists. The GEC adhered to
the deﬁnitions of PUB from the MUCOSA trial (Silverstein et al.,
1995) and the celecoxib new drug application. The incidence of
PUB and gastroduodenal (GD) ulcers was summarized using an
occurrence rate and an annual incidence rate. Additionally, the
vital signs, clinical laboratory tests including blood tests, and
physical examinations of study participants were evaluated and
recorded. Based on the World Health Organization-Uppsala Mon-
itoring Center causality assessment, ADRs were categorized into
certain, probable/likely, possible, unlikely, conditional/unclassiﬁed,
and unassessable/unclassiﬁable.
Treatment efﬁcacy was evaluated by measuring the change
from baseline in the language-validated Western Ontario
McMaster Questionnaire (WOMAC) scale score (Bae et al., 2001),
the Korean Knee Score (KKS) (Kim et al., 2013), and the 100-mmFig. 1. Flowchart of patient disposition*, early stop including consent withdrawal (14)pain visual analogue scale (VAS) score during ambulation. These
scales were measured at baseline, and at 12- and 24-week out-
patient visits. Physician's global assessments of patient's response
to therapy (PGART) at weeks 12 and 24 were evaluated based on
the assessments of WOMAC, KKS, and VAS. PGART was scored on a
scale of 1–5 in which 1¼excellent, 2¼good, 3¼fair, 4¼none, and
5¼poor (eTable 4, Additional ﬁle 1).
2.5. Sample size estimation
Sample size was calculated based on the hypothesis that the
incidence of GI disorder in GCSB-5 use was not higher than that of
celecoxib use reported in the previous study (Silverstein et al.,
2000). The incidence of GI disorder for celecoxib observed in
CLASS was 29.9%; accordingly, we aimed to determine if the in-
cidence of GI disorder with GCSB-5 was lower than 29.9% in this
single-arm study. Based on the previous Phase III clinical trial, AE
incidence of GI disorder with GCSB-5 was 24.2% (Park et al., 2013).
Hence, if the incidence of GI disorder with GCSB-5 had been 24.2%,
the required sample size to demonstrate superiority of GCSB-5 in a
one-sample study was 594 subjects for a 5% two-sided signiﬁcance
level and 90% power. Thus, assuming a drop-out rate of 20%, 743
participants were needed.
2.6. Statistical analysis
All participants who received at least one dose of the study
drug were included in the safety analysis set (Fig. 1). The partici-
pants who took the study drug for at least 12 weeks and had the
efﬁcacy evaluation at week 12 were included in the full analysis
(FA) set. The per protocol (PP) set consisted of the participants, prohibited medication (7), failure of follow-up (4), AE or SAE (3) and others (1).
Table 1
Baseline characteristics of patients receiving GCSB-5 at least once (safety set).
Baseline variable GCSB-5 (n¼756)
Age, mean (range) 59.7 (22–81)
o50 y, n (%) 78 (10.3)
50–60o y, n (%) 290 (38.4)
60–70o y, n (%) 285 (37.7)
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lation. The efﬁcacy analysis was conducted using the FA set and PP
set. The last observation carried forward (LOCF) method was ap-
plied to the missing data for the efﬁcacy analysis. To evaluate the
changes from the baseline to the ﬁnal visit, a paired t-test or
Wilcoxon signed-rank test was used. All data analyses were per-
formed using SAS
s
, and all statistical tests were two-sided and
assumed a 5% signiﬁcance level. Because the study was a single-
arm study, the safety data were summarized using the 95% two-
sided conﬁdence interval (CI). For comparisons between the GCSB-
5 and celecoxib safety data, an independent t-test or the Mann
Whitney test was used for continuous data, whereas the Chi-
square or Fisher's exact test was used for categorical data.Smoking status, n (%)
Non-smoking 711 (94.1)
Smoking 45 (6.0)
Alcohol use, n (%)
None 589 (77.9)
Use 167 (22.1)
Height, mean (range), cm 157.8 (139–182.6)
Weight, mean (range), kg 62.1 (42.0–110.0)
Pregnancy test, n (%)
Tested and negative 78 (10.3)
Not tested 678 (89.7)
Male 153 (22.6)
Postmenopausal 459 (67.7)
Surgically sterilized 66 (9.7)
Duration of disease, mean (SD), y
Osteoarthritis 3.0 (4.2)






Potential risk factor, %
History of gastrointestinal bleeding 0.0
History of gastrointestinal ulcer 2.9





SD, standard deviation; Min, minimum; Max, maximum
Note: Denominator of percentage is the number of subjects in the column.3. Results
3.1. Characteristics of the participants
A total of 842 patients were screened at 19 academic institu-
tions from May 2012 to June 2013. Eighty-one patients failed to
meet the inclusion criteria and 761 patients were enrolled (Fig. 1).
The baseline characteristics of the 756 participants who received
at least one dose of GCSB-5 are presented in Table 1. A total of 629
participants (82.7%) completed the GCSB-5 study (eTable 5, Addi-
tional ﬁle 1) and the overall compliance rate, calculated as the
percentage of GCSB-5 consumed versus the number of capsules
prescribed, was over than 95% at each interval (eTable 6, Addi-
tional ﬁle 1).
3.2. Safety
Total 749 treatment emergent adverse events (TEAEs) from 333
participants (44.0%, 333/756) with 240 ADRs from 138 participants
(18.3%, 138/756) were reported in the safety evaluation (Table 2).
Of these, 632 TEAEs (84.4%) were mild cases, 102 (13.6%) moderate
cases and 15 (2.0%) severe cases. Eleven participants (1.5%) ex-
perienced 11 serious adverse events (SAEs); 10 events were
deemed not-related to the study drug by the investigators, and
1 event was considered unclassiﬁable (eTable 7, Additional ﬁle 1).
3.2.1. GI disorders
A total of 179 participants (23.7%, 179/756) reported experien-
cing a GI disorder-related TEAE at least once. The most commonly
reported GI disorders were dyspepsia (11.1%), constipation (3.2%)
and upper abdominal pain (2.8%) (Table 2). ADRs were observed in
138 (18.3%) participants. Among them, 108 participants experi-
enced GI disorder-related ADRs. A serious ADR was reported in
1 case, which was “reﬂux esophagitis.”
Thirty suspected PUB cases from 15 participants were referred
to the GEC, and the GEC adjudicated that none of the cases met
PUB criteria (eTable 3, Additional ﬁle 1). Of the 30 suspected PUB
cases, 17 cases from 11 participants were deemed “non-PUB”; 15
cases from 9 participants were judged to be miscellaneous GI
symptoms, and 2 cases from 2 participants were found to be non-
ulcer bleeding. The remaining 13 cases from 4 participants were all
adjudicated to be not clinically signiﬁcant (NCS) AEs. Hence, the
annual incidence rate of PUB and GD ulcers was 0% among the 756
participants (Table 3).
Of the initial cohort of 756 participants who received at least
one dose of the study drug, 132 were dropped during the study
period. Among the 132 participants, 36 (4.8%, 36/756) dropped out
of the study because of GI disorders (Table 4). The results of the
subgroup analysis for GI disorders showed that participant's age,
gender, duration of OA, use of low dose aspirin, use of rescue
medication, presence of Helcobacter pylori infection, and NSAIDuse at baseline did not signiﬁcantly affect the incidence of GI
disorder or the drop-out rate. Participants with high compliance
showed a lower incidence of GI disorder and a lower drop-out rate
(Table 4).
3.2.2. Other adverse events
The TEAEs and ADRs are summarized in Table 2. The incidence
of dyspepsia was highest at 11.1%, followed by nasopharyngitis
(8.2%), headache (4.0%), and constipation (3.2%). None of the
changes in the laboratory tests or physical examinations observed
between baseline and 24 weeks were considered clinically
meaningful. No signiﬁcant differences were observed in any of the
vital sign categories. Among the categories of laboratory tests, the
red blood cell count, hemoglobulin, hematocrit, platelet count,
prothrombine time, cholesterol level and glucose level were
Table 2
Incidence of treatment emergent adverse events and adverse drug reactions (safety set).














Total incidence 749 333 44.0 240 138 18.3
Gastrointestinal disorders 302 179 23.7 171 108 14.3
Dyspepsia 110 84 11.1 71 57 7.5
Constipation 24 24 3.2 15 15 2.0
Abdominal pain, upper 26 21 2.8 18 14 1.9
Nausea 22 18 2.4 14 10 1.3
Abdominal pain 11 11 1.5 5 5 0.7
Abdominal distension 9 9 1.2 5 5 0.7
Gastritis 9 9 1.2 3 3 0.4
Diarrhea 9 7 0.9 5 3 0.4
Abdominal discomfort 7 7 0.9 6 6 0.8
Gastritis atrophic 7 7 0.9 4 4 0.5
Reﬂux esophagitis 7 7 0.9 4 4 0.5
Vomiting 6 6 0.8 1 1 0.1
Dry mouth 5 5 0.7 3 3 0.4
Gastroesophageal reﬂux disease 5 5 0.7 3 3 0.4
Othersa 45 44 5.8 14 13 1.7
Infections and infestations 109 84 11.1 2 2 0.3
Nasopharyngitis 74 62 8.2 1 0.1 1
Cystitis 10 8 1.1 – – –
Othersa 25 24 3.2 1 0.1 1
Musculoskeletal and connective tissue
disorders
85 66 8.7 9 8 1.1
Back pain 20 18 2.4 – – –
Musculoskeletal pain 14 13 1.7 2 2 0.3
Pain in extremity 13 12 1.6 – – –
Arthralgia 6 6 0.8 1 1 0.1
Myalgia 6 5 0.7 1 1 0.1
Musculoskeletal stiffness 5 5 0.7 1 1 0.1
Othersa 20 20 2.6 4 3 0.4
Nervous system disorders 84 59 7.8 18 11 1.5
Headache 45 30 4.0 9 5 0.7
Dizziness 20 17 2.2 9 7 0.9
Othersa 18 17 2.2 – – –
Skin and subcutaneous tissue disorders 48 40 5.3 14 12 1.6
Pruritus 22 17 2.2 8 6 0.8
Urticaria 8 8 1.1 3 3 0.4
Othersa 18 17 2.2 3 3 0.4
General disorders and administration
site conditions
33 22 2.9 14 11 1.5
Face edema 7 6 0.8 5 4 0.5
Othersa 26 21 2.8 9 7 0.9
Miscellaneousb 88 74 9.8 12 10 1.3
a Less than 5 patients for each category (based on TEAEs) were included to others.
b For miscellaneous, all subjects in each category (based on TEAEs) were less than 5.
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the changes of these parameters were not large (eTable 8, Addi-
tional ﬁle 1). No signiﬁcant differences were observed in any of
other laboratory categories. In addition, no signiﬁcant abnormal
results were observed upon physical examination.3.2.3. Comparison of the safety results with the CLASS data (Silver-
stein et al., 2000)
The incidence of GI disorder with GCSB-5 was signiﬁcantly
lower than that of the historical rate reported for celecoxib (23.7%
vs. 31.4%, po0.001). The difference in annual rate of PUB and GD
ulcers between GCSB-5 and celecoxib was highly signiﬁcantly
(0.0% vs. 2.2%, p¼0.004). The drop-out rate also was signiﬁcantly
lower in the current study than in the celecoxib study (4.8% vs.
8.7%, po0.001).3.3. Efﬁcacy
Efﬁcacy analysis revealed signiﬁcant improvement of all para-
meters (Fig. 2). The WOMAC and KKS scores signiﬁcantly improved
between baseline and 24 weeks. Additionally, GCSB-5 use sig-
niﬁcantly reduced the pain VAS score by 18.9725.5 in FA set
(po0.001) and 20.2724.9 in PP set (po0.001). According to the
PGART scale, the treatment effect at 24 weeks was excellent in 146
participants (22.2%), good in 390 participants (59.3%), fair in 100
participants (15.2%), none in 18 participants (2.7%), and poor in
4 participants (0.6%) (eTable 9, Additional ﬁle 1). The treatment
response rate at 24 weeks, which was composed of excellent,
good, and fair in this study, was 96.7%.
4. Discussion
This study was conducted to evaluate the safety and efﬁcacy of
Table 3








Total number of cases adjudicated
for ulcer or ulcer complication
30 15 2.0
Number of adjudicated cases not
meeting the deﬁnition of a gastro-
duodenal ulcer or ulcer complication
Esophageal disease 0 0 –
Gastroduodenitis 0 0 –
Colonic or small bowel disease 0 0 –




Anemia 0 0 –
Cholelithiasis 0 0 –
Subtotal 17 11 1.5
Number of adjudicated cases meeting
the deﬁnition of a gastroduodenal
ulcer or ulcer complication
Gastroduodenal ulcers 0 0 –
Ulcer complications 0 0 –
Bleeding 0 0 –
Perforation 0 0 –
Ulcer obstruction 0 0 –
Subtotal 0 0 –




Annualized rateb (PUB) 0 0 –
PUB, perforation, ulcer obstruction, or bleeding; NCS, not clinically signiﬁcant;
Patient days, Days from ﬁrst medication date to last medication date or to onset
date of adverse event
a Number of case are displayed as number of subjects [number of events].
b (Events/patient days/365.25)*100.
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tients. GCSB-5 taken twice daily for 24 weeks showed a favorable
safety and efﬁcacy proﬁle and was well tolerated. Only a small
proportion of participants experienced AEs with a few serious AEs.
The incidence of GI disorders with 24-week administration of
GCBS-5 was low. In addition, no PUB and GD ulcers were observed.
Conversely, the prevalence of GD ulcers is approximately 15–45%
in patients who administered NSAIDs regularly (Laine et al., 1999;
Laine, 2001). The components of GCSB-5 are thought to have ac-
tive antioxidant properties, to decrease nitric oxide production,
and to yield analgesic and anti-inﬂammatory effects (Park et al.,
2013). Among several actions, the anti-inﬂammatory effects of
Eucommia ulmoides, a component of GCSB-5, were established by
elucidation of the suppression of COX-2 levels in macrophages
(Kim et al., 2009). Although it is impossible to compare directly the
results with previous studies because the study designs were not
standardized, the absence of PUB and GD ulcers in this study im-
plies that GCSB-5 is safe with regard to the GI system. Further, the
incidence of ADRs was 18.3% in the present study, which was
consistent with previous ﬁndings (Park et al., 2013). Despite the
long-term administration of GCSB-5, no increases in the incidence
of ADRs were observed in the present study. Additionally, the in-
cidence of GI ADRs in patients treated with celecoxib in other
studies was 22–25% (Hochberg et al., 2011; Park et al., 2013). In this
study, however, only 14.2% of the patients treated with GCSB-5 for
24 weeks reported GI ADRs. The ADR-related discontinuation rate
(3.8%) was also lower than the rates previously reported in toler-
ability studies with other NSAIDs (4.8–8.0%) (Fan et al., 2009;Hochberg et al., 2011; Lehmann et al., 2005). Collectively, the re-
sults of this study indicate that GCSB-5 is associated with lower
rates of GI disorders, including serious complications such as PUB
or GD ulcers.
In accordance with a previous study (Park et al., 2013), we
found that GCSB-5 appeared efﬁcacious for the treatment of OA.
The minimal clinically important differences (MCID) in WOMAC
for OA of the knee or hip are reportedly 9.1–11.1 points (Ehrich
et al., 2000; Tubach et al., 2005). In this study, the signiﬁcant
improvement in WOMAC scores (8 at week 12 and 12 at week
24) was comparable to reported MCID values. In a previous study,
the improvement in 100 mm pain VAS for knee OA was 19.9 over
the baseline value (Tubach et al., 2005). Hence, the improvement
in VAS score in the present study (18.9) was also comparable to the
previous report.
In this study, the secondary goal was to compare the GCSB-5 GI
safety data with the previously reported CLASS celecoxib safety
data. In this study, the incidence of PUB or GD ulcers and the drop-
out rate due to GI disorders were all signiﬁcantly lower than the
corresponding values in CLASS (po0.001 and po0.001, respec-
tively). Overall, this study showed that the frequency of GI dis-
orders caused by GCSB-5 was much lower, including incidence of
serious complications such as PUBs or GD ulcers. The direct
comparison of the data from the two studies, however, should
have signiﬁcant limitations, including differences in the propor-
tion of patients using NSAIDs at the study onset (81.4% in CLASS
data vs 10.3% in the present study) and the duration of OA(10.3
years in CLASS vs. 3.0 years in this study). The use of NSAIDs at
study onset may have increased the occurrence of GI disorders,
and an increased duration of OA may also have led to an increased
incidence of GI disorders. In this study, differences in the risk of GI
disorders between aspirin users and non-users were not sig-
niﬁcant (p¼0.370) (Table 4). However, the corresponding increase
from 29.9% to 37.0% in the celecoxib patients according to aspirin
use was signiﬁcant (po0.001) (Silverstein et al., 2000). Therefore,
the differences in the baseline prognostic factors between the
GCSB-5 and the celecoxib safety data may diminish the sig-
niﬁcance of the differences in GI safety results between the cur-
rent GCSB-5 data and CLASS celecoxib data. Nevertheless, it should
be noted that none of the participants with GCSB-5 in the present
study experienced PUB or GD ulcers, which suggests that GCSB-5
is safe to use in OA patients. Nonetheless, the safety and efﬁcacy of
GCSB-5 should be assessed in a more diverse population of OA
patients.
The strengths of this study are that a high proportion of the
study population (629/756, 83.2%) completed the GCSB-5 study for
24 weeks, and the overall compliance rate was very high (92.3%).
Most prospective studies designed to assess the efﬁcacy and safety
of NSAIDs in patients with OA reported a 28–35% discontinuation
rate (Bello et al., 2015; Chopra et al., 2013; Silverstein et al., 2000).
Hence, the current results imply that the high rate of study com-
pletion seems to be due to the low rate and reduced severity of
AEs. Consequently, the current safety study and prior efﬁcacy
study indicate that GCSB-5 could be an alternative medication for
the treatment of OA.5. Conclusion
This 24-week open-label study demonstrated that the safety
and efﬁcacy proﬁle of a new therapeutic agent, GCSB-5, for pa-
tients with osteoarthritis are comparable to a previously published
study with celecoxib. The results of this study indicate that GCSB-5
can be used for a long-term treatment of patients with knee OA
with a comparable gastrointestinal safety proﬁle to celecoxib.
Table 4
Subgroup analysis: gastrointestinal disorders and drop-out (safety set).
Gastrointestinal disorders Drop-out
All N¼756 N¼132
Gastrointestinal disorders, n (%) 179 (23.7) 36 (4.8)1
Two-sided 95% conﬁdence interval (20.7, 26.9) (3.4, 6.5)
Age group Z65 years (N¼187) o65 years (N¼569) p-value Z65 years (N¼187) o65 years (N¼569) p-value
Gastrointestinal disorders, n (%) 37 (19.8) 142 (25.0) 0.1492 9 (4.8) 27 (4.8) 0.9702
Two-sided 95% conﬁdence interval (14.3, 26.2) (21. 5, 28.7) (2.2, 8.9) (3.2, 6.8)
Gender Male (N¼153) Female (N¼603) p-value Male (N¼153) Female (N¼603) p-value
Gastrointestinal disorders, n (%) 28 (18.3) 151 (25.0) 0.0802 5 (3.3) 31 (5.1) 0.4013
Two-sided 95% conﬁdence interval (12.5, 25.4) (21.6, 28.7) (1.1, 7.5) (3.5, 7.2)
Duration of osteoarthritis Z5 years (N¼193) o5 years (N¼563) p-value Z5 years (N¼193) o5 years (N¼563) p-value
Gastrointestinal disorders, n (%) 52 (26.9) 127 (22.6) 0.2162 14 (7.3) 22 (3.9) 0.0602
Two-sided 95% conﬁdence interval (20.8, 33.8 ) (19.2, 26.2) (4.0, 11.9) (2.5, 5.9)
Aspirin Taken (N¼67) Not Taken (N¼689) p-value Taken(N¼67) Not Taken (N¼689) p-value
Gastrointestinal disorders, n (%) 19 (28.4) 160 (23.2) 0.3452 5 (7.5) 31 (4.5) 0.2393
Two-sided 95% conﬁdence interval (18.0, 40.7) (20.1, 26.6) (2.5, 16. 6) (3.1, 6.3)
Rescue medication Taken (N¼604) Not Taken (N¼152) p-value Taken (N¼604) Not Taken (N¼152) p-value
Gastrointestinal disorders, n (%) 144 (23.8) 35 (23.0) 0.8332 26 (4.3) 10 (6.6) 0.2392
Two-sided 95% conﬁdence interval (20.5, 27.5) (16.6, 30.5) (2.8, 6.2) (3.2, 11.8)
H. pylori Positive (N¼403) Negative (N¼351) p-value Positive (N¼403) Negative (N¼351) p-value
Gastrointestinal disorders, n (%) 102 (25.3) 77 (21.9) 0.2782 22 (5.5) 14 (4.0) 0.3452
Two-sided 95% conﬁdence interval (21.1, 29.9) (17.7, 26.6) (3.5, 8.2) (2.2, 6.6)
NSAIDs use at baseline Taken (N¼78) Not Taken (N¼678) p-value Taken (N¼78) Not Taken (N¼678) p-value
Gastrointestinal disorders, n(%) 22 (28.2) 157 (23.2) 0.3212 3 (3.9) 33 (4.9) 1.0003
Two-sided 95% conﬁdence interval (18.6, 39.5) (20.0, 26.5) (0.8, 10.8) (3.4, 6.8)
Compliance 90% or higher (N¼597) Less than 90% (N¼159) p-value 90% or higher (N¼597) Less than 90% (N¼159) p-value
Gastrointestinal disorders, n (%) 124 (20.8) 55 (34.6) o0.0012 10 (1.7) 26 (16.4) o0.0012
Two-sided 95% conﬁdence interval (17.6, 24.3) (27.2, 42.5) (0.8, 3.1) (11.0, 23.0)
Note: Denominator of percentage is the number of subjects in the column.
a Percentage of patients who dropped-out due to GI disorder in total participants.
b Chi square test.















Fig. 2. The changes of WOMAC, KKS, and pain VAS score from baseline to week 24 on full analysis set and per protocol set. Bars and error bars represent mean scores and
standard deviation of each test, respectively. GCSB-5 signiﬁcantly improved all efﬁcacy tests on full analysis set (A) and per protocol set (B). †, po0.001 with Wilcoxon
signed-rank test; ‡, po0.001 with Paired t-test.
C.-W. Ha et al. / Journal of Ethnopharmacology 189 (2016) 310–318 317Author Contributions
Conception and design:
Seong-Il Bin and Chul-Won Ha.
Analysis and interpretation of the data:
All authors.
Drafting of the article or Critical revision of the article for
important intellectual content:
Yong-Beom Park and Chul-Won Ha.





Seong-Il Bin and Chul-Won Ha.
Collection and assembly of data:
All authors.Role of the funding source
This trial is funded by Greencross Corp. (South Korea). The
funder does not have any role in this study other to provide
funding and all authors are independent from the funder.Conﬂict of interests
The authors declare that they have no competing interests.Acknowledgements
This study was supported by the Green Cross Corporation,
South Korea.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.jep.2016.05.031.References
American College of Rheumatology Subcommittee on Rheumatoid Arthritis
Guidelines, 2002. Guidelines for the management of rheumatoid arthritis: 2002
update. Arthritis Rheum. 46, 328–346.
Angermann, P., 2005. Avocado/soybean unsaponiﬁables in the treatment of knee
and hip osteoarthritis. Ugeskr. Laege. 167, 3023–3025.
Bae, S.C., Lee, H.S., Yun, H.R., Kim, T.H., Yoo, D.H., Kim, S.Y., 2001. Cross-cultural
adaptation and validation of Korean Western Ontario and McMaster Uni-
versities (WOMAC) and Lequesne osteoarthritis indices for clinical research.
Osteoarthr. Cartil. 9, 746–750.
Bello, A.E., Kent, J.D., Grahn, A.Y., Ball, J., Holt, R.J., 2015. One-year open-label safety
evaluation of the ﬁxed combination of ibuprofen and famotidine with a pro-
spective analysis of dyspepsia. Curr. Med. Res. Opin. 31, 397–405.
Bombardier, C., 2002. An evidence-based evaluation of the gastrointestinal safety of
coxibs. Am. J. Cardiol. 89, 3D–9D.
Brown, E.G., Wood, L., Wood, S., 1999. The medical dictionary for regulatory ac-
tivities (MedDRA). Drug Saf. 20, 109–117.
Cha, B.C., Lee, E.H., 2009. HPLC analysis and screening of standard compound on
Saposhnikoviae radix for standardization of GCSB-5 preparation. Korean J.
Pharm. 40, 103–108.
Cha, B.C., Lee, E.H., 2010. HPLC analysis and screening of standard compound on
Cibotii rhizoma for standardization of GCSB-5 preparation. Korean J. Pharm. 41,
48–53.
Chopra, A., Saluja, M., Tillu, G., Sarmukkaddam, S., Venugopalan, A., Narsimulu, G.,
Handa, R., Sumantran, V., Raut, A., Bichile, L., Joshi, K., Patwardhan, B., 2013.
Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in
the treatment of symptomatic knee osteoarthritis: a randomized, double-blind,
controlled equivalence drug trial. Rheumatology 52, 1408–1417.
Conaghan, P.G., Dickson, J., Grant, R.L., 2008. Care and management of OA in adults:
summary of NICE guidance. BMJ 336, 502–503.
Ehrich, E.W., Davies, G.M., Watson, D.J., Bolognese, J.A., Seidenberg, B.C., Bellamy, N.,
2000. Minimal perceptible clinical improvement with the Western Ontario and
McMaster Universities osteoarthritis index questionnaire and global assess-
ments in patients with osteoarthritis. J. Rheumatol. 27, 2635–2641.
Fan, Y., He, X., Zhou, S., Luo, A., He, T., Chun, Z., 2009. Composition analysis and
antioxidant activity of polysaccharide from Dendrobium denneanum. Int. J. Biol.
Macromol. 45, 169–173.
Gabriel, S.E., Jaakkimainen, L., Bombardier, C., 1991. Risk for serious gastrointestinal
complications related to use of nonsteroidal anti-inﬂammatory drugs: a meta-
analysis. Ann. Intern. Med. 115, 787–796.
García Rodríguez, L.A., Jick, H., 1994. Risk of upper gastrointestinal bleeding and
perforation associated with individual non-steroidal anti-inﬂammatory drugs.
Lancet 343, 769–772.
Hawkey, C.J., 1990. Non-steroidal anti-inﬂammatory drugs and peptic ulcers. BMJ
300, 278–284.
J., Heo, (1613 A.D.). 1999. Dong Ui Bo Gam [The precious mirror of oriental medi-
cine]. Namsandang. Seoul.
Hochberg, M.C., Fort, J.G., Svensson, O., Hwang, C., Sostek, M., 2011. Fixed-dose
combination of enteric-coated naproxen and immediate-release esomeprazole
has comparable efﬁcacy to celecoxib for knee osteoarthritis: two randomized
trials. Curr. Med. Res. Opin. 27, 1243–1253.
Kim, B.H., Park, K.S., Chang, I.M., 2009. Elucidation of anti-inﬂammatory potencies
of Eucommia ulmoides bark and Plantago asiatica seeds. J. Med. Food 12,
764–769.
Kim, H.W., Kwon, Y.B., Ham, T.W., Roh, D.H., Yoon, S.Y., Han, H.J., Kang, S.K., Lee, H.J.,
Mar, W.C., Yang, I.S., Beitz, A.J., Lee, J.H., 2002. The antinociceptive and anti-
C.-W. Ha et al. / Journal of Ethnopharmacology 189 (2016) 310–318318inﬂammatory effect of ethylacetate extracts from Bang-Poong (Radix lede-
bouriellae) on the Freund's adjuvant-induced arthritis in rats. J. Vet. Sci. 3,
343–349.
Kim, J.G., Ha, J.K., Han, S.B., Kim, T.K., Lee, M.C., 2013. Development and validation of
a new evaluation system for patients with a ﬂoor-based lifestyle: the Korean
knee score. Clin. Orthop. Relat. Res. 471, 1539–1547.
Kim, J.K., Park, S.W., Kang, J.W., Kim, Y.J., Lee, S.Y., Shin, J., Lee, S., Lee, S.M., 2012.
Effect of GCSB-5, a herbal formulation, on monosodium iodoacetate-induced
osteoarthritis in rats. Evid. Based Complement. Altern. Med. 2012, 730907.
Laine, L., 2001. Approaches to nonsteroidal anti-inﬂammatory drug use in the high-
risk patient. Gastroenterology 120, 594–606.
Laine, L., Harper, S., Simon, T., Bath, R., Johanson, J., Schwartz, H., Stern, S., Quan, H.,
Bolognese, J., 1999. A randomized trial comparing the effect of rofecoxib, a
cyclooxygenase 2-speciﬁc inhibitor, with that of ibuprofen on the gastro-
duodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis En-
doscopy Study Group. Gastroenterology 117, 776–783.
Lee, C.H., Kim, S.H., Lee, J.S., Cho, K.H., Kim, J.S., Cho, S.H., Lee, S.M., 2005. Evaluation
of the antinociceptive properties of GCSB-5, a herbal formulation. Korean J.
Pharm. 36, 299–304.
Lee, E.H., Cha, B.C., 2008. Quantitative analysis of Acanthopanacis cortex and
Achyranthis radix for standardization of GCSB-5 preparation. Korean J. Pharm.
39, 316–323.
Lee, E.H., Cha, B.C., 2009. Quantitative analysis of Clycine Semen Nigra and Eu-
commiae Cortex for standardization of GCSB-5 preparation. Korean J. Pharm.
40, 18–24.
S., Lee, (1590 A.D.). 1978. Bon Cho Gang Mok [Compendium of Material medica].
ChungKuK ChungEuiHak. Peking.
Lehmann, R., Brzosko, M., Kopsa, P., Nischik, R., Kreisse, A., Thurston, H., Litschig, S.,
Sloan, V.S., 2005. Efﬁcacy and tolerability of lumiracoxib 100 mg once daily in
knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and
celecoxib. Curr. Med. Res. Opin. 21, 517–526.
Lung, Y.B., Seong, S.C., Lee, M.C., Shin, Y.U., Kim, D.H., Kim, J.M., Jung, Y.K., Ahn, J.H.,
Seo, J.G., Park, Y.S., Lee, C.S., Roh, K.J., Han, C.K., Cho, Y.B., Chang, D.Y., Kwak, W.J.,
Jung, K.O., Park, B.J., 2004. A four-week, randomized, double-blind trial of the
efﬁcacy and safety of SKI306X: a herbal anti-arthritic agent versus diclofenac in
osteoarthritis of the knee. Am. J. Chin. Med. 32, 291–301.
Manek, N.J., Lane, N.E., 2000. Osteoarthritis: current concepts in diagnosis andmanagement. Am. Fam. Phys. 61, 1795–1804.
Ownby, S.L., Fortuno, L.V., Au, A.Y., Grzanna, M.W., Rashmir-Raven, A.M., Frondoza,
C.G., 2014. Expression of pro-inﬂammatory mediators is inhibited by an avo-
cado/soybean unsaponiﬁables and epigallocatechin gallate combination. J. In-
ﬂamm. 11, 8.
Park, Y.G., Ha, C.W., Han, C.D., Bin, S.I., Kim, H.C., Jung, Y.B., Lim, H.C., 2013. A pro-
spective, randomized, double-blind, multicenter comparative study on the
safety and efﬁcacy of Celecoxib and GCSB-5, dried extracts of six herbs, for the
treatment of osteoarthritis of knee joint. J. Ethnopharmacol. 149, 816–824.
Silverstein, F.E., Faich, G., Goldstein, J.L., Simon, L.S., Pincus, T., Whelton, A., Makuch,
R., Eisen, G., Agrawal, N.M., Stenson, W.F., Burr, A.M., Zhao, W.W., Kent, J.D.,
Lefkowith, J.B., Verburg, K.M., Geis, G.S., 2000. Gastrointestinal toxicity with
celecoxib vs nonsteroidal anti-inﬂammatory drugs for osteoarthritis and
rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib
Long-term Arthritis Safety Study. JAMA 284, 1247–1255.
Silverstein, F.E., Graham, D.Y., Senior, J.R., Davies, H.W., Struthers, B.J., Bittman, R.M.,
Geis, G.S., 1995. Misoprostol reduces serious gastrointestinal complications in
patients with rheumatoid arthritis receiving nonsteroidal anti-inﬂammatory
drugs. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.
123, 241–249.
Song, Y.W., Lee, E.Y., Koh, E.M., Cha, H.S., Yoo, B., Lee, C.K., Baek, H.J., Kim, H.A., Suh,
Y.I., Kang, S.W., Lee, Y.J., Jung, H.G., 2007. Assessment of comparative pain relief
and tolerability of SKI306X compared with celecoxib in patients with rheu-
matoid arthritis: a 6-week, multicenter, randomized, double-blind, double-
dummy, phase III, noninferiority clinical trial. Clin. Ther. 29, 862–873.
Tubach, F., Ravaud, P., Baron, G., Falissard, B., Logeart, I., Bellamy, N., Bombardier, C.,
Felson, D., Hochberg, M., van der Heijde, D., Dougados, M., 2005. Evaluation of
clinically relevant changes in patient reported outcomes in knee and hip os-
teoarthritis: the minimal clinically important improvement. Ann. Rheum. Dis.
64, 29–33.
Yoo, W.H., Yoo, H.G., Park, S.H., Baek, H.J., Lee, Y.J., Shim, S.C., Kang, S.W., Kim, H.A.,
Song, J.S., Suh, C.H., Choi, S.J., Yoon, B.Y., Tae, D.N., Ko, H.S., Song, Y.W., 2014.
Efﬁcacy and safety of PG201 (Layla
s
) and celecoxib in the treatment of symp-
tomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active
drug comparative, parallel-group, non-inferiority, phase III study. Rheumatol.
Int. 34, 1369–1378.
